

Contents

1. Description
 - 1.1 Principle of the REAl ease Fluorochrome Technology
 - 1.2 Applications
 - 1.3 Reagent and instrument requirements
2. Protocol for removal of REAl ease Complexes
3. Example of immunofluorescent staining and removal of the REAl ease Complex

Warnings

Reagents contain sodium azide. Under acidic conditions sodium azide yields hydrazoic acid, which is extremely toxic. Azide compounds should be diluted with running water before discarding. These precautions are recommended to avoid deposits in plumbing where explosive conditions may develop.

1. Description


This product is for research use only.

Components	1 mL REAl ease Release Reagent 2× 1 mL REAl ease Stop Reagent
Capacity	For 5×10 ⁸ total cells, up to 50 reactions.
Product format	All reagents are supplied in buffer containing 0.05% sodium azide. REAl ease Release Reagent contains stabilizer.
Storage	Store protected from light at 2–8 °C. Do not freeze. The expiration date is indicated on the vial label.

1.1 Principle of the REAl ease Fluorochrome Technology

The REAl ease Fluorochrome Technology relies on recombinantly engineered antibody fragments (REAl ease Complex) which are characterized by low epitope binding affinities and no binding to Fc receptors.

First, cells are labeled with a fluorochrome-conjugated REAl ease Complex. Then, the REAl ease Complex can be removed from the cell surface by the addition of the REAl ease Release Reagent. Cells are washed using the REAl ease Stop Reagent and can now be relabeled with different fluorochrome-conjugated REAl ease Complexes.



1.2 Applications

- Removal of fluorochrome-conjugated REAlease Complexes.

1.3 Reagent and instrument requirements

- Fluorochrome-conjugated REAlease Complexes, e.g., REAlease CD19-FITC. For more information about antibodies refer to www.miltenyibiotec.com/antibodies.
- Buffer: Prepare a solution containing phosphate-buffered saline (PBS), pH 7.2, 0.5% bovine serum albumin (BSA), and 2 mM EDTA by diluting MACS® BSA Stock Solution (#130-091-376) 1:20 with autoMACS® Rinsing Solution (#130-091-222). Keep buffer cold (2–8 °C).

▲ **Note:** EDTA can be replaced by other supplements such as anticoagulant citrate dextrose formula-A (ACD-A) or citrate phosphate dextrose (CPD). Buffers or media containing Ca^{2+} or Mg^{2+} are not recommended for use.

2. Protocol for removal of REAlease Complexes


▲ Volumes given below are for up to 10^7 stained cells. When working with fewer than 10^7 cells, use the same volumes as indicated. When working with higher cell numbers, scale up all reagent volumes and total volumes accordingly.

▲ The recommended incubation temperature is room temperature. Lower temperatures may lead to decreased removal efficiency.

1. Determine cell number.
2. Centrifuge cell suspension at $300\times g$ for 10 minutes. Aspirate supernatant completely.
3. Resuspend up to 10^7 cells in 980 μL of buffer.
4. Add 20 μL of REAlease Release Reagent.
5. Mix well and incubate for 10 minutes in the dark at room temperature.
6. Wash cells by adding 1 mL of buffer and centrifuge at $300\times g$ for 10 minutes. Aspirate supernatant completely.
7. (Optional) For relabeling with REAlease Complexes resuspend the cell pellet in 1970 μL of buffer and add 30 μL of REAlease Stop Reagent. Mix well and centrifuge at $300\times g$ for 10 minutes. Aspirate supernatant completely. Resuspend up to 10^6 nucleated cells per 68 μL of buffer and add 30 μL of REAlease Stop Reagent. Mix well and add fluorochrome-conjugated REAlease Complexes according to the data sheet.
8. Resuspend cell pellet in a suitable amount of buffer or media for downstream application.

3. Example of immunofluorescent staining and removal of the REAlease Complex

Human peripheral blood mononuclear cells (PBMCs) were stained with REAlease CD4-FITC (B) or with the corresponding REAL Control (A). REAlease CD4-FITC was released using the REAlease Release Reagent (C). To show epitope accessibility after REAlease Complex release, the cells were washed with the REAlease Stop Reagent and restained with REAlease CD4-FITC (D). Cells were labeled with CD3 antibodies in addition and were analyzed by flow cytometry using the MACSQuant® Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide (PI) fluorescence.



Refer to www.miltenyibiotec.com for all data sheets and protocols. Miltenyi Biotec provides technical support worldwide. Visit www.miltenyibiotec.com for local Miltenyi Biotec Technical Support contact information.

Legal notices

Limited product warranty

Miltenyi Biotec B.V. & Co. KG and/or its affiliate(s) warrant this product to be free from material defects in workmanship and materials and to conform substantially with Miltenyi Biotec's published specifications for the product at the time of order, under normal use and conditions in accordance with its applicable documentation, for a period beginning on the date of delivery of the product by Miltenyi Biotec or its authorized distributor and ending on the expiration date of the product's applicable shelf life stated on the product label, packaging or documentation (as applicable) or, in the absence thereof, ONE (1) YEAR from date of delivery ("Product Warranty"). Miltenyi Biotec's Product Warranty is provided subject to the warranty terms as set forth in Miltenyi Biotec's General Terms and Conditions for the Sale of Products and Services available on Miltenyi Biotec's website at www.miltenyibiotec.com, as in effect at the time of order ("Product Warranty"). Additional terms may apply. BY USE OF THIS PRODUCT, THE CUSTOMER AGREES TO BE BOUND BY THESE TERMS.

THE CUSTOMER IS SOLELY RESPONSIBLE FOR DETERMINING IF A PRODUCT IS SUITABLE FOR CUSTOMER'S PARTICULAR PURPOSE AND APPLICATION METHODS.

Technical information

The technical information, data, protocols, and other statements provided by Miltenyi Biotec in this document are based on information, tests, or experience which Miltenyi Biotec believes to be reliable, but the accuracy or completeness of such information is not guaranteed. Such technical information and data are intended for persons with knowledge and technical skills sufficient to assess and apply their own informed judgment to the information. Miltenyi Biotec shall not be liable for any technical or editorial errors or omissions contained herein.

All information and specifications are subject to change without prior notice. Please contact Miltenyi Biotec Technical Support or visit www.miltenyibiotec.com for the most up-to-date information on Miltenyi Biotec products.

Licenses

This product and/or its use may be covered by one or more pending or issued patents and/or may have certain limitations. Certain uses may be excluded by separate terms and conditions. Please contact your local Miltenyi Biotec representative or visit Miltenyi Biotec's website at www.miltenyibiotec.com for more information.

The purchase of this product conveys to the customer the non-transferable right to use the purchased amount of the product in research conducted by the customer (whether the customer is an academic or for-profit entity). This product may not be further sold. Additional terms and conditions (including the terms of a Limited Use Label License) may apply.

CUSTOMER'S USE OF THIS PRODUCT MAY REQUIRE ADDITIONAL LICENSES DEPENDING ON THE SPECIFIC APPLICATION. THE CUSTOMER IS SOLELY RESPONSIBLE FOR DETERMINING FOR ITSELF WHETHER IT HAS ALL APPROPRIATE LICENSES IN PLACE. Miltenyi Biotec provides no warranty that customer's use of this product does not and will not infringe intellectual property rights owned by a third party. BY USE OF THIS PRODUCT, THE CUSTOMER AGREES TO BE BOUND BY THESE TERMS.

Trademarks

autoMACS, MACS, MACSQuant, the Miltenyi Biotec logo, and REAlease are registered trademarks or trademarks of Miltenyi Biotec and/or its affiliates in various countries worldwide.

Copyright © 2021 Miltenyi Biotec and/or its affiliates. All rights reserved.